- What is the optimal fit-for-purpose design in an oncology first-in-human trial?: 3+3 vs. Bayesian Logistic Regression Model
-
Yum SY
- KMID: 2505145
- Transl Clin Pharmacol.
- 2020 Mar;28(1):1-6.
- doi: 10.12793/tcp.2020.28.e1
-
- CITED
-
- Close
- SHARE
-
- Close
- Complex influences of gut microbiome metabolism on various drug responses
-
Chae S, Kim DJ, Cho JY
- KMID: 2505146
- Transl Clin Pharmacol.
- 2020 Mar;28(1):7-16.
- doi: 10.12793/tcp.2020.28.e3
The gut microbiome closely interacts with the host, and it has a major influence on drug response. Many studies have reported the possible microbial influences on drugs and the possible... -
- CITED
-
- Close
- SHARE
-
- Close
- Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
-
Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE
- KMID: 2505147
- Transl Clin Pharmacol.
- 2020 Mar;28(1):17-33.
- doi: 10.12793/tcp.2020.28.e4
Type 2 diabetes mellitus is a multifactorial condition characterized by high level of sugar in the blood. To control hyperglycemia, combination therapy is recommended if monotherapy fails to achieve glycemic... -
- CITED
-
- Close
- SHARE
-
- Close
- Survey of physicians' views on the clinical implementation of pharmacogenomics-based personalized therapy
-
Kim WY, Kim HS, Oh M, Shin JG
- KMID: 2505148
- Transl Clin Pharmacol.
- 2020 Mar;28(1):34-42.
- doi: 10.12793/tcp.2020.28.e6
Despite quantitative increases and qualitative advances in pharmacogenomics (PGx) research, the clinical implementation of PGx-based personalized therapy has still been limited. The objective of this study was to assess physicians'... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
-
Lee WY, Oh E, Cui M, Kim CO, Lim Y, Kim H, Park H, Yoon S, Park MS, Hong T
- KMID: 2505150
- Transl Clin Pharmacol.
- 2020 Mar;28(1):55-65.
- doi: 10.12793/tcp.2020.28.e5
YH4808 is a novel potassium-competitive acid blocker that was developed as a therapeutic agent for gastric acid-related diseases; it may replace proton pump inhibitors, which are widely used in combination... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects
-
Jin X, Kim E, Huh KY, Hwang I, Cho JY, Yu KS, Lee S
- KMID: 2505149
- Transl Clin Pharmacol.
- 2020 Mar;28(1):43-54.
- doi: 10.12793/tcp.2020.28.e2
A fixed-dose combination (FDC) of gemigliptin/metformin can improve the medication adherence in patients with type 2 diabetes mellitus (T2DM). In this study, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of... -
- CITED
-
- Close
- SHARE
-
- Close
